776 completed, 77 unknown, 38 recruiting, 21 terminated. 647 Phase 1, 187 Not applicable, 21 Phase 2, 15 Phase 3, 12 Early Phase 1.
Follow Healthy Subjects: new trials by email Literature Review of Healthy Subjects trials Research Report on Healthy Subjects
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Repeat Dose Study of the Dexmedetomidine Transdermal System in Healthy Subjects Dexmedetomidine Transdermal System (DMTS) - Healthy Subjects | Phase 1 | Not yet recruiting | Teikoku Pharma USA, Inc. | 20 | 2026-10-30 | 2026-09-14 |
| Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult Males [¹⁴C]FXS4640 - Healthy Subjects | Phase 1 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 6 | 2026-10-25 | 2026-10-13 |
| An Early Feasibility Study of the BioJet™ Oral Biotherapeutic Delivery System for Administration of Therapeutic Agents in Healthy Participants Hadlima® - Healthy Subjects | Phase 1 | Not yet recruiting | Biora Therapeutics, Inc. | 30 | 2026-10-20 | 2026-09-30 |
| Morpho-functional Evaluation of the Retina and Choroid Using Multimodal Imaging in Healthy Subjects and Patients With Retino-choroidal Diseases Retinal Diseases, Choroidal Diseases | Not yet recruiting | Fondazione G.B. Bietti, IRCCS | 125 | 2026-10-01 | 2026-09-04 | |
| A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults ABBV-7828, Placebo for ABBV-7828 - Healthy Subjects | Phase 1 | Not yet recruiting | AbbVie | 60 | 2026-09-21 | 2026-10-05 |
| A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults Itraconazole, Rifampicin, Omeprazole - Healthy Subjects | Phase 1 | Not yet recruiting | InventisBio Co., Ltd | 60 | 2026-09-16 | 2026-10-15 |
| A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon Adalimumab, Guselkumab, SDL-001 - Healthy Subjects | Phase 1 | Not yet recruiting | Surmount Services, Inc. | 18 | 2026-09-15 | 2026-08-26 |
| High Frequency Stimulation to Improve Cognition, Mobility, and Affect in Individuals With and Without Subjective Cognitive Decline Experimental -- 16.67 Hz Visual Occlusion, Control - 1Hz Visual Occlusion - Subjective Cognitive Decline (SCD), Healthy Subjects | Not applicable | Recruiting | University of Florida | 60 | 2026-08-14 | 2026-09-23 |
| Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Acute Postprandial Study High-fibre plant-based snack bar, Control snack bars - Healthy Participants, Healthy Adult Subject | Not applicable | Recruiting | Zoe Global Limited | 54 | 2026-08-14 | 2026-10-07 |
| Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Chronic Study High-fibre plant-based snack bar, Control snack bars - Healthy Participants, Healthy Adult Subject | Not applicable | Recruiting | Zoe Global Limited | 100 | 2026-08-14 | 2026-10-13 |
| A Mass Balance Study of [14C]HS-10504 [¹⁴C]HS-10504 - Healthy Subjects | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 6 | 2026-07-30 | 2026-08-14 |
| Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects YHP2508C, YHR2603 - Healthy Subjects | Phase 1 | Completed | Yuhan Corporation | 46 | 2026-07-10 | 2026-10-01 |
| Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers YHP2511, YHP2511A - Healthy Subjects | Phase 1 | Completed | Yuhan Corporation | 61 | 2026-06-23 | 2026-07-22 |
| Shoulder Strength in Baseball Players Strength and Range of Motion - Healthy Subjects | Recruiting | Loma Linda University | 120 | 2026-04-23 | 2026-08-31 | |
| A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects CM326(formulation 1), CM326(formulation 2) - Healthy Subjects | Phase 1 | Not yet recruiting | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 192 | 2026-04-20 | 2026-04-30 |
| Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes Magnetic Resonance Imaging (MRI) examination - Healthy Subjects | Not applicable | Recruiting | Central Hospital, Nancy, France | 120 | 2026-04-04 | 2026-06-12 |
| Y-Balance Test Training for Ankle Function and Lower Limb Functional Performance Y-Balance Test-Based Training Program - Healthy Subjects | Not applicable | Completed | Aveiro University | 56 | 2026-03-16 | 2026-09-22 |
| First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics ISH0688 for injection, Placebo - Healthy Subjects, Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Not yet recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 104 | 2026-03-01 | 2026-04-01 |
| Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment Aortic Regurgitation Disease, Aortic Stenosis Disease | Recruiting | Anhui Provincial Cancer Hospital | 15 | 2025-12-26 | 2026-01-20 | |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061 SYH2061, Placebo - Healthy Subjects | Phase 1 | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 40 | 2025-12-23 | 2026-06-08 |
Showing 20 of 950. Sign in to see all of them.
Diabetes Mellitus, Type 2 (8) · Alzheimer Disease (7) · Arthritis, Rheumatoid (7) · Obesity (7) · Acquired Immunodeficiency Syndrome (6) · Hyperalgesia (6) · Insulin Resistance (6) · Pulmonary Disease, Chronic Obstructive (6) · Diabetes Mellitus (5) · Infections (5) · Motor Activity (5) · Schizophrenia (5) · Cystic Fibrosis (4) · Glaucoma (4) · Overweight (4)
Pathological Conditions, Signs and Symptoms (53) · Signs and Symptoms (34) · Nutritional and Metabolic Diseases (33) · Nervous System Diseases (31) · Immune System Diseases (26) · Metabolic Diseases (26) · Mental Disorders (24) · Respiratory Tract Diseases (24) · Pathologic Processes (20) · Digestive System Diseases (19) · Glucose Metabolism Disorders (19) · Neurologic Manifestations (18) · Endocrine System Diseases (16) · Lung Diseases (16) · Central Nervous System Diseases (14)
Moxifloxacin (18) · Itraconazole (17) · Rifampin (17) · Rosuvastatin Calcium (13) · Midazolam (12) · mirabegron (12) · Metformin (11) · peficitinib (11) · Exercise (10) · aprocitentan (9) · isavuconazole (9) · Sodium Chloride (8) · dolutegravir (8) · Saline Solution (7) · Tablets (7)
GlaxoSmithKline (43) · Astellas Pharma Europe B.V. (34) · Idorsia Pharmaceuticals Ltd. (30) · Astellas Pharma Inc (29) · Wyeth is now a wholly owned subsidiary of Pfizer (25) · AstraZeneca (23) · Astellas Pharma Global Development, Inc. (20) · Pfizer (17) · Bio-innova Co., Ltd (16) · Eisai Inc. (16) · Jiangsu HengRui Medicine Co., Ltd. (12) · Torrent Pharmaceuticals Limited (11) · Actelion (9) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (9) · Viatris Innovation GmbH (8)
United States (268) · China (109) · United Kingdom (72) · Germany (64) · France (41) · Netherlands (32) · South Korea (24) · Japan (22) · Belgium (18) · Denmark (17) · Australia (16) · Spain (15) · Italy (14) · Sweden (14) · Switzerland (14)
Hala Masoud, PhD (5) · Thomas V Nowak, MD (5) · Wilhelm Kirch, MD (5)
PMID 27144617, PMID 16275600, PMID 21300053, PMID 23741350, PMID 24052307, PMID 25917876, PMID 26305798, PMID 28088251, PMID 31314925, PMID 32715381, PMID 33493503, PMID 10146588, PMID 11190378, PMID 11576045, PMID 11725167, PMID 11804862, PMID 12150380, PMID 14557228, PMID 14652490, PMID 14678841, PMID 15225175, PMID 15560360, PMID 16202520, PMID 16389894, PMID 17284637, PMID 17537681, PMID 18776138, PMID 19130989, PMID 19414625, PMID 19737151, PMID 20027598, PMID 20051587, PMID 2031066, PMID 20435707, PMID 20599188, PMID 20667792, PMID 20677228, PMID 20929592, PMID 21262998, PMID 21439804, PMID 21566204, PMID 21733603, PMID 21924360, PMID 21983216, PMID 21990103, PMID 22019281, PMID 22136279, PMID 22288567, PMID 22298568, PMID 22314101
2009 (9), 2014 (9), 2017 (9), 2015 (8), 2018 (7), 2019 (6), 2016 (5), 2008 (4), 1OT2OD028183-01 (3), 2004 (3), 1OT2OD023847-01 (2), 2023 (2), 272201600029C-P00007-9999-2 (2), 1UM1AI104681-01 (1), 2025 (1)